Clinical trials: Stage IB Pancreatic Adenocarcinoma
Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of ipilimumab when given together with gemcitabine hydrochloride in treating patients with stage III-IV or recurrent pancreatic cancer that cannot be removed by surgery.
- Conditions
- Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT01473940
- Testing
- ipilimumab, gemcitabine hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Northwestern University
Pancreas Cancer, Metastatic Pancreatic Cancer
FOLFIRINOX + NIS793 in Pancreatic Cancer
This research is being done to evaluate the safety and effectiveness of the drug NIS793 in combination with the standard of care treatment FOLFIRINOX (consists of the drugs 5-Fluorouracil (5-FU), Oxaliplatin, Irinotecan, and…
- Conditions
- Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT05417386
- Testing
- FOLFIRINOX, Oxaliplatin, Leucovorin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Colin D. Weekes, M.D., PhD
Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 Combined with Chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma…
- Trial name
- NCT07235202
- Testing
- MR001, Irinotecan Liposome Injection combined with 5-FU/LV, Nab-paclitaxel
- Where
- 18 sites in China
- Volunteers
- 45 people
- Sponsor
- Shenzhen Majory Biotechnology Co., Ltd.
Pancreatic Cancer
Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00536874
- Testing
- gemcitabine hydrochloride, oxaliplatin, protein expression analysis
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Pancreatic Cancer
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, irinotecan hydrochloride, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT01473303
- Testing
- ganitumab, fluorouracil, irinotecan hydrochloride
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer
Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer
Determine the doses and schedule appropriate for phase 2 study of sorafenib and vorinostat with concurrent gemcitabine and radiation therapy (RT) as neoadjuvant treatment of pancreatic cancer following chemotherapy.
- Conditions
- Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer
- Trial name
- NCT02349867
- Testing
- Gemcitabine, Sorafenib, Vorinostat
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Virginia Commonwealth University
Pancreatic Ductal Adenocarcinoma
Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer
The purpose of this study is to assess the safety, tolerability and efficacy of JPI-547 in combination with modified FOLFIRINOX (mFOLFIRINOX) or Gemcitabine-nab-paclitaxel (GemAbraxne) in patients with locally advanced and…
- Trial name
- NCT05257993
- Testing
- JPI-547, modified FOLFIRINOX, Gemcitabine-nab-paclitaxel
- Where
- 4 sites in South Korea
- Volunteers
- 71 people
- Sponsor
- Onconic Therapeutics Inc.